Application instructions can be found here in the Spring 2020 Growing Gene and Cell Therapy RFA.
Note to Applicants: GGACT is supported by NIH/NCATS U01TR001814—funding which will conclude on June 30, 2021. All final applications to be selected this cycle will receive support until this date; therefore, support may be limited due to procedural timelines associated with projects and/or support services.
Eligibility and Selection Criteria: Applications will be accepted from faculty members at CTSA institutions that also have established pediatric stem cell transplant programs. Corporate sponsored trials funded by NIH SBIR/STTR mechanisms to be conducted at CTSA institutions are fully eligible. While other corporate-sponsored trials conducted at CTSA institutions are eligible for support, preference will be given to NIH-funded trials, trials supported by patient advocacy groups, or public-private partnerships. Special terms and conditions may apply to corporate-sponsored trials.
Project review, selection, and prioritization will be done based on the following criteria:
- Significance: the relevance to rare pediatric diseases (fulfill an unmet clinical need) and impact of the proposed therapy (e.g. is it likely to be an improvement over standard of care?).
- Rationale/scientific merit: the project must have a compelling rationale and strong supporting preliminary data including proof of concept studies.
- Feasibility: the sponsor/principal investigator’s qualifications, commitment, and available resources to support initiation and completion of project.
Selection Process: The initial application will consist of a 2 page Letter of Intent (LOI). The LOI will be screened to examine if the proposed research project supports the goals of the cooperative and to verify which support services are requested. The screening process will be performed by the Joint Steering Committee, with final approval by the Executive Committee. Following the initial screening, the committee may request a phone call to discuss the project or provide feedback. An invitation will be sent to selected investigators to submit a full application.
Full applications will undergo reviews by the Translational Technical Steering Committee and the Regulatory Steering Committee, both of which will submit their recommendations to the Joint Steering Committee for final selection.
Notify me when the next application cycle is open: